Zobrazeno 1 - 10
of 708
pro vyhledávání: '"MET inhibitor"'
Autor:
Alessandro Inno, Giuseppe Bogina, Giulio Settanni, Matteo Salgarello, Giovanni Foti, Carlo Pomari, Vincenzo Picece, Stefania Gori
Publikováno v:
Drug Target Insights, Vol 17, Iss 1 (2023)
Optimal treatment for metastatic non-small cell lung cancer (NSCLC) with mesenchymal epithelial transition gene (MET) exon 14 skipping mutation has not been established yet. MET inhibitors were demonstrated to be effective and tolerated in patients w
Externí odkaz:
https://doaj.org/article/752f5884635e4f99ac8e878d8741dd7b
Publikováno v:
Drug Design, Development and Therapy, Vol Volume 17, Pp 761-769 (2023)
Juan Wu,1,2 Hongrong Xu,1 Hui Li,1 Lei Ma,3 Juan Chen,3 Fei Yuan,1 Lei Sheng,1 Chao Liu,1 Weili Chen,1 Xuening Li1 1Department of Clinical Pharmacology & Cancer Center, ZhongShan Hospital, Fudan University, Shanghai, People’s Republic of China; 2De
Externí odkaz:
https://doaj.org/article/45be2ac5e6e143d48ab919df5392b763
Publikováno v:
STEMedicine, Vol 4, Iss 3 (2023)
Background: DE605 is a c-MET inhibitor that can be taken orally. Sorafenib is the only treatment that has been proven to increase overall survival rates in patients with advanced hepatocellular carcinoma (HCC). However, the effectiveness of sorafenib
Externí odkaz:
https://doaj.org/article/1d4bd4204d014ea89efb536400e798a2
Autor:
Sebastian Kraus
Publikováno v:
Current Problems in Cancer: Case Reports, Vol 10, Iss , Pp 100230- (2023)
Targeted therapies are recommended for treatment of patients with non-small cell lung cancer (NSCLC) with actionable driver mutations, including those with poor performance status, who otherwise have limited treatment options. However, clinical trial
Externí odkaz:
https://doaj.org/article/547129d2555345518af346f872b75f23
Autor:
Yongfeng Yu, Jianya Zhou, Xingya Li, Koichi Goto, Xuhong Min, Kazumi Nishino, Jiuwei Cui, Lin Wu, Jun Sakakibara, Yongqian Shu, Xiaorong Dong, Lu Li, Yasuto Yoneshima, Chengzhi Zhou, Xiaoling Li, Yiping Zhang, Dingzhi Huang, Aimin Zang, Wei Zhang, Xiuwen Wang, Li Zhang, Chong Bai, Jian Fang, Lejie Cao, Yanqiu Zhao, Yan Yu, Meiqi Shi, Diansheng Zhong, Fugen Li, Meng Li, Qiuxia Wu, Jun Zhou, Minghui Sun, Shun Lu
Publikováno v:
EClinicalMedicine, Vol 59, Iss , Pp 101952- (2023)
Summary: Background: Approximately 3–4% of patients with non-small-cell lung cancer (NSCLC) have MET exon 14 (METex14) skipping mutations. We report primary results from the phase 2 stage of a phase 1b/2 study of gumarontinib, a selective, potent,
Externí odkaz:
https://doaj.org/article/7812099965ee4424acef24e171e9a49c
Autor:
Zhuo-Xun Wu, Qiu-Xu Teng, Yuqi Yang, Nikita Acharekar, Jing-Quan Wang, Min He, Sabesan Yoganathan, Jun Lin, Jian Wang, Zhe-Sheng Chen
Publikováno v:
Acta Pharmaceutica Sinica B, Vol 12, Iss 5, Pp 2609-2618 (2022)
Overexpression of ABCG2 transporter in cancer cells has been linked to the development of multidrug resistance (MDR), an obstacle to cancer therapy. Our recent study uncovered that the MET inhibitor, tepotinib, is a potent reversal agent for ABCB1-me
Externí odkaz:
https://doaj.org/article/290b0cda90f24d6583e11b6b86866a8c
Autor:
Xiaorong Dong, MD, PhD, Xingya Li, MD, Jianhua Chen, MD, Shenglin Ma, MD, Deguang Mu, MD, Jie Hu, MD, PhD, Shun Lu, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 2, Pp 100449- (2023)
Introduction: c-MET is an important therapeutic target for various cancers; however, the People’s Republic of China currently retails only one specific c-MET inhibitor. Our preclinical study has revealed the high selectivity of HS-10241 to suppress
Externí odkaz:
https://doaj.org/article/7a976e919ca64687a5bc34303f3eb7b5
Publikováno v:
Frontiers in Pediatrics, Vol 10 (2022)
Clear Cell Sarcoma (CCS), also referred to as malignant melanoma of soft parts, is a rare and aggressive malignant tumor. It comprises 1% of all soft tissue sarcomas and is known to be radio- and chemotherapy resistant. CCS shares morphological and i
Externí odkaz:
https://doaj.org/article/90d05c06606b4ca699a469194d04c963
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Xiaobo Liu, Yuzhen Li, Qian Zhang, Qingshan Pan, Pengwu Zheng, Xinyang Dai, Zhaoshi Bai, Wufu Zhu
Publikováno v:
Frontiers in Chemistry, Vol 10 (2022)
In this study, we designed and synthesized a series of novel [1,2,4]triazolo [4,3-a]pyrazine derivatives, and evaluated them for their inhibitory activities toward c-Met/VEGFR-2 kinases and antiproliferative activities against tested three cell lines
Externí odkaz:
https://doaj.org/article/910ccfd3cff647398a4d6ac448940e3b